BiotechTube

Anidulafungin/Fluconazole

Phase 3Terminated
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Candidemia

Conditions

Candidemia

Trial Timeline

Dec 1, 2010 → Nov 1, 2011

NCT ID
NCT01176058

About Anidulafungin/Fluconazole

Anidulafungin/Fluconazole is a phase 3 stage product being developed by Pfizer for Candidemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT01176058. Target conditions include Candidemia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01176058Phase 3Terminated

Competing Products

9 competing products in Candidemia

See all competitors
ProductCompanyStageHype Score
micafungin + Micafungin + CaspofunginAstellas PharmaApproved
85
MicafunginAstellas PharmaApproved
85
AmBisomeGilead SciencesApproved
84
Anidulafungin + VoriconazolePfizerApproved
84
Anidulafungin + FluconazolePfizerPhase 3
76
AnidulafunginPfizerPhase 3
76
Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + PlaceboBasilea PharmaceuticaPhase 3
72
APX001Basilea PharmaceuticaPhase 2
47
APX001Basilea PharmaceuticaPhase 2
47

Other Products from Pfizer

MeropenemApproved
84
celecoxibApproved
84
13vPnCApproved
84
EtanerceptApproved
84
AtorvastatinApproved
84